Sponsored by
This may be a breakthrough in the treatment of Glioblastomas. Teserpaturev is the new name for the treatment that we used to call G47 Delta. In the clinical trial for recurrent Glioblastoma, they had a 92.3% one year survival rate, compared to historical rates of about 15%! It should be available in Japan soon and we will work on getting it here!